arthritis - RSS Feed Directory

abortion
acid reflux
adhd
alcohol treatment
allergy
alternative medicine
alzheimers dimentia
anxiety phobia
arthritis
asthma respiratory
autism
bacteria viral
biochemistry biology
bipolar
bird flu avian flu
blood hematology
body aches
breast cancer
cancer oncology
cardiovascular cardiology
cholesterol
cleft palate
clinical drug trials
colorectal cancer
compliance
cosmetic plastic surgery
cystic fibrosis
dentistry
depression
dermatology
diabetes
disaster aid
dyslexia
ear nose throat
endocrinology
epilepsy
erectile dysfunction premature ejaculation
eye health opthamology
fertility
fitness obesity
flu sars
gastrointestinal
genetics
gout
headlines
health insurance
hearing deafness
hiv aids
homecare caregivers
huntingtons disease
hypertension
immune system
internet
irritable bowel syndrome
liver disease hepatitis
lung cancer
lupus
lymphoma leukemia
mad cow disease
medical conference
medical devices
medical malpractice
medical students
medicare medicaid
mens health
mental health
migraine headache
mri pet scan
mrsa super bug
multiple sclerosis
muscular dystrophy
neurology neuroscience
nursing
nutrition agriculture
organ transplants donation
orthopaedics
pain
parkinsons disease
pediatrics
pharmaceutical industry
pregnancy
primary care
prostrate
psychology psychiatry
public health
radiology
rehabilitation
schizophrenia
senior aging
sleep disorders
smoking
sports medicine
statins
stds sexual health
stem cell research
stroke
terrorism
tropical diseases
ulcerative colitis crohns disease
urology nephrology
veterinary
water quality
womens health obgyn

feed contents

Adolescents With Arthritis Need More Information When Transitioning To Adult Care
Helping adolescents with arthritis develop the skills and secure resources to assure that their health care needs are met as they transition to adulthood is an important issue in the U.S. In general, the frequency of which young people with special health care needs receive transition services is low and, to date, no studies have examined this frequency.
medicalnewstoday.com

Knee Replacement: Health Care Providers And Patients Differ On Views
Total knee replacement (TKR) is a common treatment for osteoarthritis, a disease affecting more than 20 million Americans. However, the surgery poses risks and both patients and physicians must carefully assess its potential benefits and harm. Studies have shown that doctor-patient communication is correlated with outcomes and that patient satisfaction and commitment to treatment are usually higher when the doctor and patient are able to agree on a number of factors.
medicalnewstoday.com

UCB Receives Complete Response Letter From U.S. FDA For Use Of Cimzia® In Rheumatoid Arthritis Patients
UCB announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) relating to the Biologics License Application (BLA) of Cimzia® (certolizumab pegol), the first PEGylated anti-TNF, for the treatment of rheumatoid arthritis (RA). As a prerequisite for approval of Cimzia®, the FDA has requested a new safety update with all clinical data including new data generated since the filing of the BLA.
medicalnewstoday.com

Can-Fite Completed Patient Enrollment For The Confirmatory Phase IIb Trial In Rheumatoid Arthritis Patients With CF101
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 230 patients in its confirmatory phase IIb RA trial. Approximately 230 patients were enrolled to this study, randomized into 3 groups treated with 0.1 mg and 4 mg of CF101, and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 30 sites in Europe and Israel.
medicalnewstoday.com

Pegloticase BLA Filing Accepted For Priority Review By FDA
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients. The FDA also granted the Company's BLA with a priority review status which accelerates the review period to six months.
medicalnewstoday.com

Potential Autoimmunity-Inducing Cells Found In Healthy Adults
It's not just patients with autoimmune diseases like lupus and rheumatoid arthritis (RA) that have self-attacking immune cells - healthy people have them too, according to a new report in the Journal of Experimental Medicine. In healthy adults, however, these cells are maintained in an 'off' state, perhaps explaining their innocuous nature.
medicalnewstoday.com

Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients received two infusions of either 500 mg or 1000 mg of Rituxan or placebo for up to two treatment courses in combination with a stable dose of MTX.
medicalnewstoday.com

Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients received two infusions of either 500 mg or 1000 mg of Rituxan or placebo for up to two treatment courses in combination with a stable dose of MTX.
medicalnewstoday.com

MabThera Inhibits The Destruction Of Joints In Patients With Early Rheumatoid Arthritis
Roche announced recently that MabThera (rituximab) can significantly inhibit structural damage to joints in patients with early rheumatoid arthritis (RA) who have not been treated with methotrexate (MTX), the current standard of care for RA treatment.
medicalnewstoday.com

Groundbreaking, Inexpensive, Pocket-sized Ultrasound Device Can Help Treat Cancer, Relieve Arthritis
A prototype of a therapeutic ultrasound device, developed by a Cornell graduate student, fits in the palm of a hand, is battery-powered and packs enough punch to stabilize a gunshot wound or deliver drugs to brain cancer patients. It is wired to a ceramic probe, called a transducer, and it creates sound waves so strong they instantly cause water to bubble, spray and turn into steam. Tinkering in his Olin Hall lab, George K. Lewis, a third-year Ph.D.
medicalnewstoday.com

CrystalGenomics Announces Positive Phase IIa Results For Osteoarthritis Study Of CG100649
CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, CA) announced positive results from a Phase IIa osteoarthritis (OA) study of the efficacy and safety of a next-generation NSAID, CG100649. The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC(TM) OA score from baseline to Day 21 (p=0.010) compared to placebo.
medicalnewstoday.com

Preventing A Recurrence Of The Northwick Park Trial
Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead. But Dr Stephen Poole, speaking at the British Pharmacological Society's Winter Meeting in Brighton, said that research is still "ongoing" to understand why the drug had such an adverse effect in the clinic but not in pre-clinical testing.
medicalnewstoday.com

Funding For Building Better Bones And Tissue In The Lab
Tissue engineering holds great promise for the treatment of conditions such as arthritis, osteoporosis, fibrosis, periodontal disease and traumatic injuries. However, bone and cartilage currently produced in the laboratory don't have sufficient strength to function in the body so they're not clinically viable. Dr.
medicalnewstoday.com

Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks Of Fentanyl Overdose
The law firm of Hissey Kientz, LLP wishes to alert patients who use the Duragesic (fentanyl) pain patch of the serious and potentially fatal health risks they may face from the use of this powerful painkilling drug. The Duragesic pain patch was first approved by the Food and Drug Administration in August 1990 to treat certain patients with chronic pain.
medicalnewstoday.com

Fighting Gum Disease With Gene Therapy
Scientists at the University of Michigan have shown that gene therapy can be used to successfully stop the development of periodontal disease, the leading cause of tooth loss in adults. The findings will be published online Dec 11 in advance of print publication in Gene Therapy.
medicalnewstoday.com

Third Osteoarthritis Study This Year Reveals Pycnogenol® Lowers Inflammatory Marker CRP
Osteoarthritis (OA), a type of arthritis caused by the breakdown and loss of cartilage, affects more than 20 million Americans. While the most common prescription to treat OA is non-steroidal anti-inflammatory drugs (NSAIDs), many seek alternative treatments because of the side effects associated with these drugs. Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, has been shown to reduce osteoarthritis in multiple studies.
medicalnewstoday.com

Mutation In Bone Marrow Cancers Blocked By Promising New Drug , May Also Help Patients With Rheumatoid Arthritis
Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers. The oral drug, called CYT387, was tested in mice as well as in human cells. In both cases, it blocked the growth of certain bone marrow cancers called myeloproliferative disorders, also referred to as MPDs. The research was presented Tuesday, Dec. 9, at 7 a.m.
medicalnewstoday.com

$12 Million In Grants To Develop Transplant And Allergy Drugs Received By REGiMMUNE
REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, has announced that it has received two separate grants totaling more than $12 million from the Japan Science and Technology Agency (JST) and from National Institute of Biomedical Innovation (NIBIO).
medicalnewstoday.com

Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results Of Phase III Study Of Milnacipran For The Management Of Fibromyalgia
Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for the management of fibromyalgia.
medicalnewstoday.com

Anika Therapeutics Completes Enrollment In MONOVISC™ Pivotal U.S. Clinical Trial
Anika Therapeutics, Inc. (NASDAQ:ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced today that it has completed enrollment for its pivotal U.S. clinical trial for MONOVISC™.
medicalnewstoday.com

POZEN Announces Positive Top Line Results For Its PN 400 Phase 3 Trials
POZEN Inc. (NASDAQ: POZN), today announced positive Phase 3 trial results for its PN 400 product candidate (enteric coated naproxen 500 mg and immediate release esomeprazole 20 mg) conducted by POZEN under an agreed Special Protocol Assessment with the FDA. Both the PN 400-301/302 studies achieved the primary endpoints.
medicalnewstoday.com

Roche And FDA Agree On Pathway Towards U.S. Approval Of ACTEMRA(R) (tocilizumab)
Roche announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA(R) (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
medicalnewstoday.com

Results From The First And Largest Collaborative Study Confirm Role Of Enbrel® In Psoriatic Arthritis
New data presented today at the 'Gene to Clinic' meeting taking place at the Royal College of Physicians in London, England, reinforce Enbrel's ability to clear skin in patients with psoriatic arthritis, an inflammatory and progressive disease associated with psoriasis.
medicalnewstoday.com

Researchers From La Jolla Institute And Albany Medical College Identify Cell Group Key To Lyme Disease Arthritis
A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease.
medicalnewstoday.com

Better Management More Important Than New Drugs For Arthritis
Although there has been an increase in the number of new arthritis treatments in recent years, the best results will come from more effective use of the drugs we have. Research published in BioMed Central's open access journal Arthritis Research and Therapy investigates the effectiveness of available arthritis drugs and concludes that better management is the most important factor.
medicalnewstoday.com

ARTHRITIS News, Sports, Shopping, Travel information

Arthritis - Rss Feed Directory